Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation Metabolic Syndrome?

被引:102
作者
Katsiki, Niki [1 ]
Perez-Martinez, Pablo [2 ,3 ]
Anagnostis, Panagiotis [1 ,4 ]
Mikhailidis, Dimitri P. [5 ]
Karagiannis, Asterios [1 ]
机构
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Lipid & Atherosclerosis Unit, Cordoba, Spain
[3] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
[4] Aristotle Univ Thessaloniki, Med Sch, Dept Obstet & Gynaecol 1, Unit Reprod Endocrinol, Thessaloniki, Greece
[5] UCL, Med Sch, Dept Clin Biochem, Royal Free Hosp Campus,Pond St, London NW3 2QG, England
关键词
Non-alcoholic fatty liver disease; metabolic syndrome; cardiovascular risk; risk factors; anti-obesity drugs; anti-diabetic drugs; hypolipidaemic drugs; antihypertensive drugs; CORONARY-HEART-DISEASE; TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR RISK REDUCTION; LIPOPROTEIN LDL SUBCLASSES; RENIN-ANGIOTENSIN SYSTEM; CHRONIC KIDNEY-DISEASE; VITAMIN-D DEFICIENCY; CLINICAL-SIGNIFICANCE; ERECTILE DYSFUNCTION; EPICARDIAL FAT;
D O I
10.2174/1570161115666170621075619
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD. In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy). Such associations highlight the common pathophysiological pathways of these metabolic disorders, although data for an independent association are not robust. Nevertheless, NAFLD may be regarded as a hepatic manifestation of MetS.
引用
收藏
页码:219 / 227
页数:9
相关论文
共 213 条
[1]  
Abdul-Ghani M, 2006, ISR MED ASSOC J, V8, P378
[2]   The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome [J].
Aguilar-Olivos, Nancy E. ;
Almeda-Valdes, Paloma ;
Aguilar-Salinas, Carlos A. ;
Uribe, Misael ;
Mendez-Sanchez, Nahum .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (08) :1196-1207
[3]   Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial [J].
Alam, Shahinul ;
Kabir, Jahangir ;
Mustafa, Golam ;
Das Gupta, Utpal ;
Hasan, S. K. M. Nazmul ;
Alam, A. K. M. Khorshed .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2016, 22 (01) :69-76
[4]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[5]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[6]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[7]  
2-S
[8]   Non-alcoholic fatty pancreas disease [J].
Alempijevic, Tamara ;
Dragasevic, Sanja ;
Zec, Simon ;
Popovic, Dragan ;
Milosavljevic, Tomica .
POSTGRADUATE MEDICAL JOURNAL, 2017, 93 (1098) :226-230
[9]   Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease [J].
Almeda-Valdes, Paloma ;
Aguilar-Olivos, Nancy ;
Uribe, Misael ;
Mendez-Sanchez, Nahum .
REVIEWS ON RECENT CLINICAL TRIALS, 2014, 9 (03) :148-158
[10]   Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].
Armstrong, Matthew James ;
Gaunt, Piers ;
Aithal, Guruprasad P. ;
Barton, Darren ;
Hull, Diana ;
Parker, Richard ;
Hazlehurst, Jonathan M. ;
Guo, Kathy ;
Abouda, George ;
Aldersley, Mark A. ;
Stocken, Deborah ;
Gough, Stephen C. ;
Tomlinson, Jeremy W. ;
Brown, Rachel M. ;
Huebscher, Stefan G. ;
Newsome, Philip N. .
LANCET, 2016, 387 (10019) :679-690